MedTrace Logo

Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer

NCT01897415 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-09-19

No results posted yet for this study

Summary

This is a Phase I safety and feasibility study. Subjects will be enrolled serially. For subject safety, the preceding subject must have completed one cycle of therapy (28 days) before the next subject can be treated. Subjects will be treated with i.v. administration of 1 to 3e8 per meter squared RNA CAR T cells three times weekly (M-W-F) for three weeks.

Conditions

  • Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (PDA)

Interventions

BIOLOGICAL

Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1

Sponsors & Collaborators

Principal Investigators

  • Gregory Beatty, MD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-12-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01897415 on ClinicalTrials.gov